Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRXF research report →
Price Chart
About the company
Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology firm, focusing its efforts on the discovery, advancement, and commercialization of innovative technologies within the biotech landscape. The company's leading therapeutic compound, EP-104IAR, is currently progressing through Phase II clinical trials.
- CEO
- James A. Helliwell FRCPC,
- IPO
- 2021
- Employees
- 21
- HQ
- Victoria, BC, CA
Get TickerSpark's AI analysis on EPRXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $108.29M
- P/E
- -6.64
- Fwd P/E
- 9.20
- PEG
- 0.30
- P/S
- 0.00
- P/B
- 3.42
- EV/EBITDA
- -3.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.29%
- ROIC
- -43.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-209,911-8.6%
- Op Income
- $-37,889,260
- Net Income
- $-38,089,240-63.8%
- EPS
- $-1.58-30.6%
- OCF Growth
- -48.7%
- FCF Growth
- -46.8%
- 52W High
- $6.78
- 52W Low
- $2.93
- 50D MA
- $4.30
- 200D MA
- $4.80
- Beta
- 1.40
- RSI (14)
- 37
- Avg Volume
- 2.42K
No earnings-call transcripts are available for EPRXF yet.
- Free Float
- 64.2%
- Shares Outstanding
- 35.62M
- Float Shares
- 22.88M
Our EPRXF coverage
Recent articles, reports, and earnings notes.
No research on EPRXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRXF report →Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Up 3.6% – What’s Next?
defenseworld.net · Feb 19
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
prnewswire.com · Apr 3
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
prnewswire.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.